GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cogstate Ltd (OTCPK:COGZF) » Definitions » GF Value
中文

Cogstate (Cogstate) GF Value

: $1.13 (As of Today)
View and export this data going back to 2010. Start your Free Trial

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-24), Cogstate's share price is $0.8431. Cogstate's GF Value is $1.13. Therefore, Cogstate's Price-to-GF-Value for today is 0.75.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Cogstate is Modestly Undervalued.

Cogstate  (OTCPK:COGZF) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Cogstate's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=0.8431/1.13
=0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cogstate GF Value Related Terms

Thank you for viewing the detailed overview of Cogstate's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Cogstate (Cogstate) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cogstate Ltd (OTCPK:COGZF) » Definitions » GF Value
Comparable Companies
ASX:ONE ASX:VHT ASX:M7T ASX:MDR ASX:ALC ASX:BMT ASX:PCK ASX:RHT ASX:IME ASX:SHG GEHC VEEV SOLVw TSE:2413 ASX:PME HQY RCM DOCS TXG EVH
Traded in Other Exchanges
CGS:Australia
Address
161 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Website
https://www.cogstate.com
Cogstate Ltd is a cognitive science company. The principal activity of the company is the sale of technology and services for the measurement of cognition, where services include scientific consultancy, project management, data management, statistical analysis, and reporting. Its operating segment includes Clinical Trials; Healthcare and Research. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.